Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV Clinic

20244 citationsJournal Article

Authors

Casey Morgan Luc · Chicago Department of Public Health

Blake Max · Ruth M. Rothstein CORE Center

Sarah E. Pérez · Ruth M. Rothstein CORE Center

Kara Herrera · Chicago Department of Public Health

Gregory Huhn · Ruth M. Rothstein CORE Center

Mark S. Dworkin · Chicago Department of Public Health

Abstract

We found high treatment satisfaction with LA-CAB+RPV in a diverse population. Participants reported moderate injection pain, which improved with time. Results suggest injectable LA-CAB+RPV will be met with acceptability across diverse participant populations.

Topics & Keywords

HIV Research and Treatment HIV/AIDS drug development and treatment HIV, Drug Use, Sexual Risk

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAIDS Journal of Acquired Immune Deficiency Syndromes

Volume 97, Issue 4, pp. 409-415

DOI: 10.1097/qai.0000000000003500

Field-Weighted Citation Impact: 1.18